Table 2.
Patient characteristics for mBCORL1.
| Parameter | wtBCORL1 | mBCORL1 | p-Value |
|---|---|---|---|
| N. of patients | 1476 | 53 | |
| Age, median (IQR) | 55 (44–65) | 52 (43–62) | 0.177 |
| Sex, n (%) | 0.044 | ||
| Female | 697 (47.2) | 33 (62.3) | |
| Male | 779 (52.8) | 20 (37.7) | |
| AML type, n (%) | 0.621 | ||
| De novo | 1244 (85.3) | 43 (82.7) | |
| sAML | 167 (11.4) | 6 (11.5) | |
| tMN | 48 (3.3) | 3 (5.8) | |
| ELN2017, n (%) | <0.001 | ||
| Favorable | 564 (41.5) | 6 (12) | |
| Intermediate | 531 (39.1) | 35 (70) | |
| Adverse | 264 (19.4) | 9 (18) | |
| Complex karyotype, n (%) | 0.975 | ||
| No | 1192 (88) | 39 (86.7) | |
| yes | 163 (12) | 6 (13.3) | |
| FLT3-ITD, n (%) | 0.782 | ||
| wt | 1138 (77.6) | 39 (75) | |
| m | 328 (22.4) | 13 (25) | |
| NPM1, n (%) | 0.006 | ||
| wt | 977 (67.3) | 45 (86.5) | |
| m | 475 (32.7) | 7 (13.5) | |
| WBC, median (IQR) in GPt/L | 20.09 (4.8–55.27) | 14.35 (3.55–54.95) | 0.340 |
| Hb, median (IQR) in mmol/L | 5.9 (5.0–7.0) | 6.2 (5.3–7.0) | 0.341 |
| Platelets, median (IQR) in GPt/L | 51 (27.0–93.3) | 50.5 (30.0–90.5) | 0.727 |
| LDH, median (IQR) in mmol/L | 452 (288.0–794.8) | 333 (254.0–621.0) | 0.053 |
| BM blasts (%), median (IQR) | 63 (44–79) | 65.25 (48.88–82.75) | 0.299 |
| PB blasts (%), median (IQR) | 40.5 (12–74) | 48.5 (15–78) | 0.419 |
wt: wild-type; m-: mutated; sAML: secondary acute myeloid leukemia; tMN: therapy-related acute myeloid leukemia; ELN2017: European Leukemia Net 2017; WBC: white blood cells; BM: bone marrow; PB: peripheral blood; n/N: number; IQR: interquartile range.